CSI Market
Sign In | Register

Twist Bioscience (TWST) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TWST Annual Cash Flow →
From Twist Bioscience through Mar 31 2025, changes in Mar 31 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
6 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-74.53
Depreciation & amortization12.61
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-5.21
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Business0.00
Share-based Compensation32.21
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Operating Lease Impairment Loss-
Business Acquisition Income Tax Benefit Due To Deferred Tax Liability-
Provision For Loan Losses Expensed-
Payment For Contingent Consideration Liability Operating Activities-
Change In Fair Value Of Acquisition Consideration-
Deconsolidation Gain Or Loss Amount-
Property Plant And Equipment Write Off-
Income taxes0.00
Realized Investment Gains (Losses), Total0.00
Accounts Receivable-11.68
Increase (Decrease) in Accounts Payable1.54
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities22.79
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-18.86
Other Working Capital-0.42
Other Noncash Income (Expense)-0.83
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-42.37
Investing Activities
Capital Expenditures-22.96
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.32
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-22.64
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.09
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-185.43
Paymentd To Repurchases Of Common Stock For Tax Withholding-
Payments To Repurchases Of Common Stock For Tax Withholding-0.01
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan2.36
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents185.43
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.44
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-65.33
Total Cash Flow-60.57
4 historic quarters locked

Sign in to unlock the full Twist Bioscience cash flow history.

Sign In Create Free Account

About Twist Bioscience Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001581280-26-000047

Figures are derived from filed reports and may be restated. Historical data is subject to revision.